Tafamidis meglumine and tafamidis capsules have received FDA approval for treatment of cardiomyopathy caused by transthyretin-mediated amyloidosis (ATTR-CM) in adults.
In this cohort study higher adherence to plant-based dietary patterns was associated with lower risk of incident HHF in adults without CHD.
In a real-world cohort of HFrEF patients starting sacrubitril/valsartan, 29.5% were women. After 7 months NYHA functional class improvement was greater in women vs. men.
In a pooled analysis of 3 HFpEF trials, CV death and HF hospitalization were increased in HFpEF patients with prior pacemaker implantation compared to those without.
ACC 2019 Previous results have shown benefits in mortality and HF hospitalization with MitraClip. New data complement the previous findings and demonstrate improved quality of life with MitraClip in HF patients with secondary MR.
ACC 2019 In the MOMENTUM 3 trial, the centrifugal-flow pump HeartMate 3 was compared with the axial-flow pump HeartMate 2 in patients with advanced HF. Prof. Uriel discusses the findings and implications of this trial.
The SwedeHF register showed a change in ejection fraction (EF) over time across EF groups of HF patients, which was linked to adverse outcomes, particularly in those transitioning to and from HFrEF.
Treatment with sacubitril/valsartan shifts BNP level distribution right-wards as compared to NT-proBNP levels, but both NPs could predict the risk of CV death or first hospitalization for HF in HFrEF patients.
A Dutch registry showed that elderly outpatient HFrEF and HFmrEF patients were treated less often with recommended types and dosages of HF medication, and received less often ICD and CRT devices.
ACC 2019 Pulmonary artery pressure-guided therapy in class III HF patients met the primary efficacy and two safety endpoints at 1 year in the CardioMEMS trial.
Pulmonary capillary wedge pressure (PCWP), BMI and stroke volume were independently associated with the presence of HFpEF, compared with healthy subjects exercising at the same workloads.
ACC 2019 In an echocardiography substudy of the COAPT trial, predictors of poor outcomes were studied in HF patients with severe secondary mitral regurgitation.